Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Pharm Res. 2014 Dec 6;32(6):1894–1906. doi: 10.1007/s11095-014-1583-0

Figure 5.

Figure 5

Plasma concentrations of GHB after oral administration of GHB (1500 mg/kg) with and without AR-C155858 (A) Intravenous AR-C155858 administration, and (B) Oral AR-C155858 administration. In the intravenous treatment group, AR-C155858 was administered as 5 mg/kg i.v. bolus and GHB was administered by oral gavage. AR-C155858 was administered either 5 minutes or 1 hour post GHB dose. In the oral treatment group, AR-C155858 and GHB were simultaneously administered by oral gavage. Data are presented as mean ± S.D., n = 4–8 in each group.